U.S. Food and Drug Administration (FDA)

FDA Direct - Special Edition of FDA Direct

In a special edition of FDA Direct, the agency’s leadership reviewed a year of restructuring, record‑setting approvals, and a forward‑looking agenda focused on speed, safety and affordability. The discussion highlighted a near‑record 67 new drug approvals, an average review time of 310 days—well under the historic four‑year benchmark—and the successful deployment of the home‑grown AI assistant “Elsa,” now used by more than 90% of reviewers to parse massive submissions. Key performance metrics were underscored, including rapid approvals such as a 44‑day review for a HER2‑mutated lung‑cancer therapy and a 55‑day review for a multiple‑myeloma drug, as well as meeting 100% of PDUFA target dates. The FDA also announced regulatory reforms that eliminate costly comparative efficacy studies for biosimilars, cut routine PK studies, and expand the priority‑voucher pilot, all aimed at reducing drug prices and accelerating access. The director cited concrete examples: 72 enforcement letters sent to curb misleading direct‑to‑consumer ads, a 20% rise in food inspections, and industry cooperation on removing petroleum‑based food dyes, with General Mills achieving its goal ahead of schedule. The AI tool’s adoption, the record device approvals (3,939), and the shift toward surprise overseas inspections illustrate a broader push toward modern, data‑driven oversight. These initiatives signal a more agile FDA that balances rapid innovation with public‑health safeguards, potentially lowering costs for patients, spurring domestic manufacturing, and reshaping how pharmaceutical and food companies engage with regulators.